Back to Search Start Over

Plethora of Antibiotics Usage and Evaluation of Carbapenem Prescribing Pattern in Intensive Care Units: A Single-Center Experience of Malaysian Academic Hospital

Authors :
Chee Lan Lau
Petrick Periyasamy
Muhd Nordin Saud
Sarah Anne Robert
Lay Yen Gan
Suet Yin Chin
Kiew Bing Pau
Shue Hong Kong
Farah Waheeda Tajurudin
Mei Kuen Yin
Sheah Lin Ghan
Nur Jannah Azman
Xin Yun Chua
Poy Kei Lye
Stephanie Wai Yee Tan
Dexter Van Dort
Ramliza Ramli
Toh Leong Tan
Aliza Mohamad Yusof
Saw Kian Cheah
Wan Rahiza Wan Mat
Isa Naina-Mohamed
Source :
Antibiotics, Vol 11, Iss 9, p 1172 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Excessive antibiotic consumption is still common among critically ill patients admitted to intensive care units (ICU), especially during the coronavirus disease 2019 (COVID-19) period. Moreover, information regarding antimicrobial consumption among ICUs in South-East Asia remains scarce and limited. This study aims to determine antibiotics utilization in ICUs by measuring antibiotics consumption over the past six years (2016–2021) and specifically evaluating carbapenems prescribed in a COVID-19 ICU and a general intensive care unit (GICU) during the second year of the COVID-19 pandemic. (2) Methods: This is a retrospective cross-sectional observational analysis of antibiotics consumption and carbapenems prescriptions. Antibiotic utilization data were estimated using the WHO Defined Daily Doses (DDD). Carbapenems prescription information was extracted from the audits conducted by ward pharmacists. Patients who were prescribed carbapenems during their admission to COVID-19 ICU and GICU were included. Patients who passed away before being reviewed by the pharmacists were excluded. (3) Results: In general, antibiotics consumption increased markedly in the year 2021 when compared to previous years. Majority of carbapenems were prescribed empirically (86.8%). Comparing COVID-19 ICU and GICU, the reasons for empirical carbapenems therapy in COVID-19 ICU was predominantly for therapy escalation (64.7% COVID-19 ICU vs. 34% GICU, p < 0.001), whereas empirical prescription in GICU was for coverage of extended-spectrum beta-lactamases (ESBL) gram-negative bacteria (GNB) (45.3% GICU vs. 22.4% COVID-19 ICU, p = 0.005). Despite microbiological evidence, the empirical carbapenems were continued for a median (interquartile range (IQR)) of seven (5–8) days. This implies the need for a rapid diagnostic assay on direct specimens, together with comprehensive antimicrobial stewardship (AMS) discourse with intensivists to address this issue.

Details

Language :
English
ISSN :
20796382
Volume :
11
Issue :
9
Database :
Directory of Open Access Journals
Journal :
Antibiotics
Publication Type :
Academic Journal
Accession number :
edsdoj.f05e6f27da4e6bbe03751fa04d5d62
Document Type :
article
Full Text :
https://doi.org/10.3390/antibiotics11091172